Form 4: Outlook Therapeutics CEO Buys Shares
Insider Transaction (Form 4)
Robert Charles Jahr, Chief Executive Officer and a Director of Outlook Therapeutics, Inc., purchased 303,030 shares of common stock on August 14, 2026.
Summary
- Open-market purchase: acquired 151,515 Common Stock on August 14, 2026; holds 151,515 after (Direct).
- Open-market purchase: acquired 151,515 Warrants (right to buy) on August 14, 2026; holds 151,515 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $0, committing personal capital to the stock.
Insider Transactions
Robert Charles Jahr — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Open-market purchase | Common Stock | 151,515 | — | — | 151,515 |
| 2026-08-14 | Open-market purchase | Warrants (right to buy) | 151,515 | — | — | 151,515 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Open-market purchase (151,515 shares) |
| 2026-08-14 | Open-market purchase (151,515 shares) |
Keywords
insider transaction, Form 4, OTLK, Outlook Therapeutics, Inc., bullish, Robert Charles Jahr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.